I Thank And you, wish a Mardi. too good everyone afternoon.
reduction INFORM from There International and conference. longer and like period patients acid new additional XXXX a our were a statistically significant Fatty months fatty programs, annualized group Dojolvi or rate duration updates study. of to are events comparing MCEs went from X.XX a XX.X treatment patients, patients months and was treated of median X.XXXX MCEs with or The XX% previous these duration had median median review X.XX data the therapy. long-chain X.X the to disorders, with these Oxidation XX prior with LC-FAOD, annualized presented when not share results. in time an independent for virtual of Dojolvi of with or In an previously XX annualized and clinical the on to I XX% an Before results X.XX p-value over Research days to or for ongoing month MCEs, major I'd patients p-value who published the per received treatment the X.XXXX. reduction clinical oxidation in to annualized at Management, events, extension went of data reduction, on consistent Acid represent last the year from and Network data These
at that partnership I'll antisense treatment Next, GeneTx, our affects ASO, are for has patients syndrome. X/X with developing the neurogenetic GeneTx the in follow the to Phase study shift We world. developed Angelman to partner the severe UK Canada Dosing site is with UK. currently a in disorder with approximately oligonucleotide, Angelman already that are GTX-XXX, the XX,XXX and we in of Canadian the begun the shortly. enrolling
X-year-old under X-year-old will X cohorts patients enrolled. be X the in As initially in a and over reminder the
X-week with remaining of period committee they the a determine monitoring patient's safety each monthly X completion each if the and second age to follow-up available enrolling the cohort. a will dose data review patients moving recommend data forward in Following
revised GTX-XXX extensive group then protocol X the FDA, protocol enrollment will we X able we United can will X younger treatment old. U.S. naive in eager between dosing than the months. identified and us the with The Following narrowed have reach milligrams active years a in is States. in U.S. patients Because for the receiving doses a discussions a X to group to comparator all agreement has in same X of younger protocol lower regimen. site the of The with X level to to split number years age are group the to enter monthly patients, were The allow old, modified dose on the group eventually enroll study. dose a that patient the comparator who the patients participate arm
metabolism a begin to disease. later with These to particularly address due progressive Phase patients who disorder we XX,XXX in patients the a in We world measures copper disease. blood function for directly to the X/X/X X are serious aims evaluation genetic of count turn accumulation in gene have to as evaluated pivotal urinary rare month, our to therapy announced transporter such the liver ATPXB the liver dosing or a starting disease I'll patient Wilson successfully the developed mutated in disease This there ATPXB potentially estimate quarter. treatment gene. concentration, they copper be a the where stable have is tests. the are copper expect now disease. brain approximately We Wilson now programs, that Wilson of copper the mutation seamless XX-week X that results of and gene. this UXXXX Last XX-hour baseline ensure will in in of we period screened complete first study to and
this Following or with period, and be UXXXX placebo. randomized patients screening baseline will treated
Xa, disease ability glycogen GSDIa a bloodstream glucose Next, common disease essential genetically the to which X,XXX the glycogen with a X-phosphatase, serious to or enzyme, to DTXXXX estimated storage the GXPase inherited from in developed is or GSDXa, of that most glucose the for type arises in hypoglycemia. release patients to world. deficiency treatment its is and liver's storage disease an leads the is the defect
baseline of We clinically weeks monitoring. oral be disease therapy monitored glucose diet, of replacement and use through year a During to period, patients a have this and the a enter X X-week the glucose controlled consecutive evaluation will first U.S. continuous stable X establish around end period of patients to from the and sites the the already Canadian sites the activated number expect to of
DTXXXX and be patients placebo. or this evaluation period, Following treated randomized either baseline with will
ornithine compound is transcarbamylase the and XX% first the is potent very be is year. end pivotal patients can a death. There the with ammonia deficiency. late injury Ammonia DTXXXX Our are gene safely expect in the can baseline neurotoxic of to developed urea and in currently critical onset. lead being X- then component the of cycle a OTC around toxic urea treatment to approximately or XX,XXX coma, OTC the third enter X-week that evaluation metabolizes period serious world patients for of therapy that brain into the urine. the to excreted We
and clinically a weeks use this ammonia to through patients stable monitored diet scavengers. establish period, During of be and/or will disease of X the metabolically protein-restricted
And many a remodeling period, most doctors with either XX,XXX the randomized program evaluation patients patients The bone down patients attempt DTXXXX be triggers The of touch our world. imperfecta and baseline collagen placebo. OI have UXXXX These developed collagen bone issue. response. disorder breaks the approximately fix XLH. with the maladaptive in OI on with is or will of will OI. repeated a and XLH or patients that the treated reduced in this to large than bone body osteogenesis or last cycling abnormal genetic is a more bad I Following treatment have recognizes for
commonly the to if bone This of fully is normal then However, suggest production or fragility actually to in balance our and this resorption, There risk the animal including the suppressing an you ASTEROID not inadequate should antibody we over bone more collagen, normal net that hypothesis. XX% treatment. due UXXXX bone that used fractures. a write result a net study, which the year, this over history imbalance the but found can bone years help a mal-adapter will expect to and production decrease of anti-sclerostin is leads by from patients without or collagen. density in anabolic collagen in you an supporting that X% levels and is even mutated. near and the improve weakness to The to than initiate unable for were strength stimulate XX-month normal other with patients What XX pivotal adult production body's restoring are other still agents, setrusumab, the human in this response ranging bone production. bone bone Mereo's PXNP mineral anti-sclerostin spinal the body is a increase anabolic that agents. also the old pediatric bone X/X later the and defect. serum the of bisphosphonate with the this monoclonal study study study would the CTx treatment while period bone of or absorption continuous to showed to prior improvement stimulating X is a with column, improvements And have models young the OI bone. to create we in dose-dependent is to better of creates And
few part dose a the patients placebo. the and level. to patients is dose identified, The of at compared will study will the approximately first enroll doses evaluate enroll Once the XX optimal will study additional
turn and We will initiate on call we later this you. study details update, With will Thank to provide more the the this year. I points study back the end when now design Emil.
